Navigation Links
Verenium Appoints John F. Dee to Board of Directors
Date:5/12/2008

- Adds significant strategic biotech business experience -

CAMBRIDGE, Mass., May 12 /PRNewswire-FirstCall/ -. Verenium Corporation (Nasdaq: VRNM), a pioneer in the development of next-generation cellulosic ethanol and high-performance specialty enzymes, today announced the appointment of John F. Dee to its Board of Directors. The Company also announced that Geoffrey Hazlewood, Ph.D., Senior Vice President of Research, has resigned for personal reasons effective May 31, 2008 and will be returning to his native England. Dr. Hazlewood will remain as an exclusive consultant to the Company and will also join its scientific advisory board, enabling him to play an ongoing role in bringing many of Verenium's important research projects to a successful conclusion.

"We are very pleased that John has joined the Verenium Board, as his extensive executive-level experience working with emerging-growth companies in strategic, financial and operational development will contribute valuable perspective while the Company rapidly accelerates into a commercial-scale producer of next-generation biofuels," said Carlos A. Riva, President and Chief Executive Officer at Verenium. "I'd also like to thank Geoff Hazlewood for his many years of significant service and contributions to Verenium and look forward to his continuing involvement."

Mr. Dee served as President, Chief Executive Officer, and Director of Hypnion, Inc., a privately-held neurosciences drug discovery company, from its founding in July 2000 through its $315 million acquisition by Eli Lilly and Company in April 2007. Before Hypnion, Mr. Dee spent three years as a "turn- around" CEO, specializing in reviving under-performing biotechnology companies including Genta, Inc. Prior
'/>"/>

SOURCE Verenium Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Verenium Reports Financial Results for the First Quarter 2008
2. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
3. Verenium Explores Bacterial Genes Inside Termite Guts to Understand How Wood is Broken Down and Converted to Energy
4. Verenium Corporation to Present at the Pacific Growth Equities 2007 Clean Technology & Industrial Growth Conference
5. Verenium Advances Its Development Work With Cargill on a New Food-Related Product
6. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
7. Cytochroma Appoints R. Richard Wieland II As CFO
8. InSet Technologies Appoints Jon Tremmel to its Board of Directors
9. Nventa Appoints John Varian to Board of Directors
10. Kendle Appoints Patricia Williams Vice President, Commercial Operations
11. Biomoda Appoints Three Business Leaders to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015  RegeneRx Biopharmaceuticals, Inc. ... in the scientific journal, Expert Opinion on Biological ... colleague, Dr. Zhenggang Zhang , at the Henry ... reported that Thymosin beta 4 (TB4) has the capacity ... 24 hours or more post-injury, leading to neurological recovery ...
(Date:3/3/2015)... New Jersey (PRWEB) March 03, 2015 ... has announced today that it has acquired The ... Terms of the transaction were not announced. , ... services to the energy sector including oil and ... energy, and fossil and nuclear power sectors. The ...
(Date:3/3/2015)... 03, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Gene Therapy - ... , Gene therapy technologies are ... and cell therapy with genetically modified vectors. Gene ... and various routes of administration as well as ...
(Date:3/3/2015)... , March 3, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... sustainable chemicals, today announced it has initiated commissioning activities ... in Sarnia, Ontario , Canada.  ... approximately five months, with the facility being in commercial ... be completed in two months and it is carrying ...
Breaking Biology Technology:Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3BioAmber Begins Commissioning of Sarnia Commercial Plant 2BioAmber Begins Commissioning of Sarnia Commercial Plant 3
... INDIANAPOLIS, March 7 Eli Lilly and Company,(NYSE: ... its AIR(R),Insulin program, which was being conducted in partnership ... clinical development as a potential,treatment for type 1 and ... not a result of any observations during AIR Insulin ...
... Kendle (Nasdaq: KNDL ), a,leading, global ... Executive Officer Candace Kendle, PharmD, and,President and Chief ... to sell shares of the company,s common stock ... part of their personal,ongoing long-term strategy for tax ...
... treatment ... disease, BIRMINGHAM, Ala., March 7 Atherotech, Inc., a,cardio-diagnostic ... in Booth 21041 at the American College of Cardiology,(ACC) 57th ... 1, 2008, at the McCormick Place Convention Center in,Chicago, Ill., ...
Cached Biology Technology:Lilly Announces Termination of AIR Insulin Program 2Lilly Announces Termination of AIR Insulin Program 3Lilly Announces Termination of AIR Insulin Program 4Kendle Leaders Adopt 10b5-1 Trading Plans 2Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago 2
(Date:3/2/2015)... VILNIUS, Lithuania , March 2, 2015   ... AI technologies, today introduced the SentiGaze Software Development ... developers to create applications that use off-the-shelf webcams to ... a user gazes at a monitor. Heatmaps can be ... determining the effectiveness of online advertising. The SDK can ...
(Date:2/23/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announced today ... DISTRIBUTED VOICE DIRECTED PAYMENT METHOD AND SYSTEM. ... payment method. Payment accounts may be selected via voice ... if both the speech (the word associated with the ...
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62/113114 for DISTRIBUTED METHOD ... The patent further establishes NXT-ID,s position in ... intellectual property portfolio the ability for multiple devices to ...
Breaking Biology News(10 mins):Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3
... funded by the Office of Naval Research (ONR) were ... Engineers (PECASE), the nation,s highest honor for young scientists ... selection of these six individuals underscores ONR,s fundamental objective, ... by leveraging the ideas of the best and brightest ...
... is available in German . , ... more complex structures and better-adapted organisms. This is all ... Especially in small asexual populations that do not recombine ... known as Muller,s ratchet in evolutionary biology. The ratchet, ...
... scientists like it when the results of measurements fit with ... and compare their values, the results are rarely "smooth". A ... is: how much nitrogen is being fixed in the ocean ... is important to predicting future climate development. All organisms need ...
Cached Biology News:ONR-funded young innovators recognized by President 2Populations survive despite many deleterious mutations 2Populations survive despite many deleterious mutations 3How much nitrogen is fixed in the ocean? 2
Anti-gp340 Monoclonal Antibody Description: 100 g Research Focus: cancer & cell proliferation Storage: -20C Shipping Temperature: 4C...
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
... BRF2 Immunogen Synthetic peptide: QAARQAATSVPNPP, corresponding ... BRF2. Reactivity / Specificity Cross-reacts with ... Background Information BRF2 is one of the ... factor complex required for transcription of genes with ...
Kinase Buffer can be used to assay protein kinase activity...
Biology Products: